Time-Resolved Autoantibody Profiling Facilitates Stratification of Preclinical Type 1 Diabetes in Children
David Endesfelder,Wolfgang Zu Castell,Ezio Bonifacio,Marian Rewers,William A Hagopian,Jin-Xiong She,Åke Lernmark,Jorma Toppari,Kendra Vehik,Alistair J K Williams,Liping Yu,Beena Akolkar,Jeffrey P Krischer,Anette-G Ziegler,Peter Achenbach,TEDDY Study Group,Kimberly Bautista,Judith Baxter,Daniel Felipe-Morales,Kimberly Driscoll,Brigitte I Frohnert,Marisa Gallant,Patricia Gesualdo,Michelle Hoffman,Rachel Karban,Edwin Liu,Jill Norris,Adela Samper-Imaz,Andrea Steck,Kathleen Waugh,Hali Wright,Olli G Simell,Annika Adamsson,Suvi Ahonen,Heikki Hyöty,Jorma Ilonen,Sanna Jokipuu,Leena Karlsson,Miia Kähönen,Mikael Knip,Mirva Koreasalo,Kalle Kurppa,Tiina Latva-Aho,Maria Lönnrot,Markus Mattila,Elina Mäntymäki,Katja Multasuo,Tiina Niininen,Sari Niinistö,Mia Nyblom,Paula Ollikainen,Petra Rajala,Jenna Rautanen,Anne Riikonen,Minna Romo,Suvi Ruohonen,Juulia Rönkä,Satu Simell,Tuula Simell,Maija Sjöberg,Aino Stenius,Sini Vainionpää,Eeva Varjonen,Riitta Veijola,Suvi M Virtanen,Mari Vähä-Mäkilä,Mari Åkerlund,Katri Lindfors,Desmond Schatz,Diane Hopkins,Leigh Steed,Jennifer Bryant,Janey Adams,Katherine Silvis,Michael Haller,Melissa Gardiner,Richard McIndoe,Ashok Sharma,Stephen W Anderson,Laura Jacobsen,John Marks,P D Towe,Anette G Ziegler,Andreas Beyerlein,Anita Gavrisan,Cigdem Gezginci,Anja Heublein,Michael Hummel,Sandra Hummel,Annette Knopff,Charlotte Koch,Sibylle Koletzko,Claudia Ramminger,Roswith Roth,Marlon Scholz,Joanna Stock,Katharina Warncke,Lorena Wendel,Christiane Winkler,Daniel Agardh,Carin Andrén Aronsson,Maria Ask,Jenny Bremer,Ulla-Marie Carlsson,Corrado Cilio,Emelie Ericson-Hallström,Annika Fors,Lina Fransson,Thomas Gard,Rasmus Bennet,Carina Hansson,Susanne Hyberg,Hanna Jisser,Fredrik Johansen,Berglind Jonsdottir,Silvija Jovic,Helena Elding Larsson,Marielle Lindström,Markus Lundgren,Maria Månsson-Martinez,Maria Markan,Jessica Melin,Zeliha Mestan,Caroline Nilsson,Karin Ottosson,Kobra Rahmati,Anita Ramelius,Falastin Salami,Sara Sibthorpe,Anette Sjöberg,Birgitta Sjöberg,Carina Törn,Anne Wallin,Åsa Wimar,Sofie Åberg,Michael Killian,Claire Cowen Crouch,Jennifer Skidmore,Ashley Akramoff,Jana Banjanin,Masumeh Chavoshi,Kayleen Dunson,Rachel Hervey,Rachel Lyons,Arlene Meyer,Denise Mulenga,Jared Radtke,Davey Schmitt,Julie Schwabe,Sarah Zink,Dorothy Becker,Margaret Franciscus,MaryEllen Dalmagro-Elias Smith,Ashi Daftary,Mary Beth Klein,Chrystal Yates,Sarah Austin-Gonzalez,Maryouri Avendano,Sandra Baethke,Rasheedah Brown,Brant Burkhardt,Martha Butterworth,Joanna Clasen,David Cuthbertson,Christopher Eberhard,Steven Fiske,Dena Garcia,Jennifer Garmeson,Veena Gowda,Kathleen Heyman,Belinda Hsiao,Francisco Perez Laras,Hye-Seung Lee,Shu Liu,Xiang Liu,Kristian Lynch,Colleen Maguire,Jamie Malloy,Cristina McCarthy,Aubrie Merrell,Steven Meulemans,Hemang Parikh,Ryan Quigley,Cassandra Remedios,Chris Shaffer,Laura Smith,Susan Smith,Noah Sulman,Roy Tamura,Ulla Uusitalo,Ponni Vijayakandipan,Keith Wood,Jimin Yang,Dongmei Miao,Polly Bingley,Alistair Williams,Kyla Chandler,Olivia Ball,Ilana Kelland,Sian Grace,Ben Gillard,William Hagopian,Henry Erlich,Steven J Mack,Anna Lisa Fear,Sandra Ke,Niveen Mulholland,Kasia Bourcier,Thomas Briese,Suzanne Bennett Johnson,Eric Triplett
DOI: https://doi.org/10.2337/db18-0594
IF: 7.7
Diabetes
Abstract:Progression to clinical type 1 diabetes varies among children who develop β-cell autoantibodies. Differences in autoantibody patterns could relate to disease progression and etiology. Here we modeled complex longitudinal autoantibody profiles by using a novel wavelet-based algorithm. We identified clusters of similar profiles associated with various types of progression among 600 children from The Environmental Determinants of Diabetes in the Young (TEDDY) birth cohort study; these children developed persistent insulin autoantibodies (IAA), GAD autoantibodies (GADA), insulinoma-associated antigen 2 autoantibodies (IA-2A), or a combination of these, and they were followed up prospectively at 3- to 6-month intervals (median follow-up 6.5 years). Children who developed multiple autoantibody types (n = 370) were clustered, and progression from seroconversion to clinical diabetes within 5 years ranged between clusters from 6% (95% CI 0, 17.4) to 84% (59.2, 93.6). Children who seroconverted early in life (median age <2 years) and developed IAA and IA-2A that were stable-positive on follow-up had the highest risk of diabetes, and this risk was unaffected by GADA status. Clusters of children who lacked stable-positive GADA responses contained more boys and lower frequencies of the HLA-DR3 allele. Our novel algorithm allows refined grouping of β-cell autoantibody-positive children who distinctly progressed to clinical type 1 diabetes, and it provides new opportunities in searching for etiological factors and elucidating complex disease mechanisms.